Daewoong Pharmaceutical Co., Ltd (KRX:069620)

Market Cap	1.39T
Revenue (ttm)	1.42T
Net Income (ttm)	24.73B
Shares Out	11.51M
EPS (ttm)	2,149.65
PE Ratio	56.20
Forward PE	10.90
Dividend	600.00 (0.50%)
Ex-Dividend Date	Dec 27, 2024

Volume	21,288
Average Volume	25,435
Open	118,500
Previous Close	119,200
Day's Range	118,500 - 120,900
52-Week Range	100,100 - 164,400
Beta	0.78
RSI	40.38
Earnings Date	May 14, 2025

About Daewoong Pharmaceutical

Daewoong Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1945
• Employees: 1,727
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 069620

Financial Performance

In 2024, Daewoong Pharmaceutical's revenue was 1.42 trillion, an increase of 3.44% compared to the previous year's 1.38 trillion. Earnings were 24.73 billion, a decrease of -79.68%.